An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

Objective:This study was designed to investigate treatment satisfaction in patients and Health Care Professionals (HCP) and to evaluate the safety and tolerability of subcutaneous (SC) trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC).Mat...

Full description

Bibliographic Details
Main Authors: İrfan Cicin, Mohammed Oukkal, Hassen Mahfouf, Amel Mezlini, Blaha Larbaoui, Slim Ben Ahmed, Hassan Errihani, Khalid Alsaleh, Rhizlane Belbaraka, Perran Fulden Yumuk, Burce Goktas, Mustafa Özgüroğlu
Format: Article
Language:English
Published: Galenos Publishing House 2022-01-01
Series:European Journal of Breast Health
Subjects:
subcutaneous
trastuzumab
breast cancer
her2
patient satisfaction
Online Access: http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/an-open-label-multinational-multicenter-phase-b-st/50673

Internet

http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/an-open-label-multinational-multicenter-phase-b-st/50673

Similar Items